Last updated: September 24, 2026
FLOXIN is the former U.S. brand name for ofloxacin, a fluoroquinolone antibacterial developed by Daiichi Sankyo. The brand has lost U.S. market exclusivity, and current commercial activity is concentrated in low-cost generic ofloxacin tablets, ophthalmic solutions, and otic solutions. FLOXIN does not have a meaningful standalone U.S. revenue stream, and its financial trajectory is defined by generic erosion, safety restrictions affecting systemic fluoroquinolones, and continued use in selected ophthalmic and otic indications.
What is FLOXIN and which products carry the brand?
FLOXIN is a brand associated primarily with ofloxacin, a synthetic fluoroquinolone antibiotic. The historical product portfolio included oral tablets and otic formulations. Ofloxacin is also marketed through generic ophthalmic products and, in some markets, branded products outside the United States.
| Product |
Active ingredient |
Historical use |
Current U.S. commercial status |
| FLOXIN tablets |
Ofloxacin |
Respiratory, urinary, skin, sexually transmitted and other bacterial infections |
Brand-level commercial presence largely ended; generic ofloxacin remains available |
| FLOXIN Otic |
Ofloxacin |
Acute otitis externa and otitis media with tympanostomy tubes |
Generic ofloxacin otic products remain available |
| Ofloxacin ophthalmic |
Ofloxacin |
Bacterial conjunctivitis and corneal infections |
Generic products remain available |
| Ofloxacin tablets |
Ofloxacin |
Systemic antibacterial treatment |
Generic products remain available, subject to fluoroquinolone safety restrictions |
The U.S. Food and Drug Administration approved oral FLOXIN under New Drug Application 19-735. Ofloxacin ophthalmic and otic products were later marketed through separate regulatory pathways and generic applications. Current product availability varies by dosage form, manufacturer, wholesaler inventory, and state purchasing contracts.
What is the FDA regulatory status of FLOXIN?
FLOXIN is no longer a commercially important protected brand in the U.S. FDA market. Ofloxacin remains an approved active ingredient in generic drug products.
The FDA has maintained substantial safety restrictions for systemic fluoroquinolones. The agency has warned about disabling and potentially permanent adverse effects involving tendons, muscles, joints, nerves, and the central nervous system. In 2016, FDA required labeling changes stating that the risks of systemic fluoroquinolones generally outweigh the benefits for patients with acute bacterial sinusitis, acute bacterial exacerbation of chronic bronchitis, and uncomplicated urinary tract infections when alternative treatments are available.[1]
In 2018, FDA required additional labeling changes concerning blood glucose disturbances and certain mental-health adverse effects. In 2021, the agency added a warning concerning the risk of aortic aneurysm and dissection for systemic fluoroquinolones in certain patients.[2]
These restrictions have had a greater commercial effect on oral ofloxacin than on ophthalmic and otic formulations. Local administration produces lower systemic exposure, and ophthalmic and otic products remain used in defined bacterial infections.
How does FDA regulation differ by dosage form?
Oral ofloxacin is affected by class-wide fluoroquinolone warnings, antimicrobial stewardship programs, and prescriber preference for alternative antibiotics.
Ophthalmic and otic ofloxacin face fewer systemic safety concerns but compete with ciprofloxacin, moxifloxacin, gatifloxacin, polymyxin B combinations, and other topical anti-infectives. The principal commercial issue in these segments is price competition rather than patent exclusivity.
What patents protect FLOXIN and ofloxacin?
The original U.S. patent estate for ofloxacin has expired. No active composition-of-matter patent provides current U.S. exclusivity for FLOXIN or generic ofloxacin.
Ofloxacin was developed by Daiichi Pharmaceutical, now part of Daiichi Sankyo. Historical U.S. patent protection covered the quinolone compound and related pharmaceutical applications. The original patent term has long ended, and generic manufacturers have had access to the active ingredient for many years.
| Patent category |
Historical status |
Current commercial effect |
| Ofloxacin compound patent |
Expired |
No remaining composition-of-matter barrier |
| Original oral formulation protection |
Expired or no longer commercially relevant |
No meaningful brand protection |
| Ophthalmic formulation patents |
Any historical protection has expired or is not a material barrier to generic entry |
Multiple generic competitors |
| Otic formulation protection |
No current broad exclusivity barrier |
Generic competition established |
| Method-of-use patents |
Historical claims are not a current barrier to ordinary ofloxacin use |
Labeling and clinical guidelines drive demand |
| Manufacturing patents |
May exist for specific processes in individual jurisdictions |
Do not generally block U.S. finished-dose competition |
The key patent conclusion is straightforward: FLOXIN’s commercial decline results from completed patent expiry and generic substitution, not from a pending near-term loss of exclusivity.
When did FLOXIN lose exclusivity?
FLOXIN lost meaningful U.S. exclusivity after the expiration of its original patent and regulatory exclusivity periods. Generic ofloxacin products entered the U.S. market in the 1990s, materially changing the product’s economics.
The principal milestones were:
| Period |
Event |
Commercial effect |
| 1980s |
U.S. launch and expansion of ofloxacin products |
Daiichi established the FLOXIN franchise |
| Early to mid-1990s |
Generic ofloxacin approvals began |
Price competition increased |
| Late 1990s |
Broad generic substitution developed |
Brand share declined |
| 2000s |
Safety concerns and antibiotic stewardship reduced systemic fluoroquinolone use |
Oral demand weakened |
| 2010s |
Generic topical products became the dominant U.S. channel |
Brand economics largely disappeared |
| Current market |
Generic ofloxacin remains available by dosage form |
Revenue is distributed among generic manufacturers |
Exact product-level market exclusivity dates depend on the NDA, dosage form, patent listing history, and applicable pediatric or regulatory exclusivity. They do not restore commercial protection for the FLOXIN brand.
What is the Orange Book status of FLOXIN?
The FDA Orange Book is the primary U.S. reference for approved drug products, therapeutic equivalence evaluations, and listed patent information. FLOXIN’s historical Orange Book entries do not provide an active patent shield against current generic ofloxacin products.
The Orange Book distinguishes between:
- Approved reference products
- Generic products with therapeutic-equivalence ratings
- Patent listings submitted by NDA holders
- Exclusivity periods
- Discontinued products
A discontinued brand may remain relevant as a reference product or historical regulatory entry even when the commercial product is no longer sold. That status should not be interpreted as ongoing market exclusivity.
For ofloxacin, the practical Orange Book conclusion is that generic competition is established, and no current broad patent listing supports a protected FLOXIN franchise in the United States.[3]
Which companies compete with FLOXIN and generic ofloxacin?
FLOXIN competes primarily with generic manufacturers rather than with an active branded manufacturer. The generic supply base has historically included major U.S. and international manufacturers such as Teva, Sandoz, Hikma, Mylan or Viatris, Cipla, Dr. Reddy’s Laboratories, and other FDA-approved suppliers, depending on dosage form and market period.
Competition differs by product:
Oral ofloxacin competitors
Oral ofloxacin competes with:
- Ciprofloxacin
- Levofloxacin
- Moxifloxacin
- Trimethoprim-sulfamethoxazole
- Nitrofurantoin for selected urinary infections
- Beta-lactam antibiotics
- Macrolides and tetracyclines for selected respiratory indications
Oral ofloxacin has lost clinical and commercial share because prescribers often select other agents with stronger current guideline support, more favorable resistance profiles, or better-established indications.
Ophthalmic competitors
Generic ofloxacin ophthalmic solution competes with:
- Ciprofloxacin ophthalmic
- Moxifloxacin ophthalmic
- Gatifloxacin ophthalmic
- Tobramycin
- Polymyxin B and trimethoprim combinations
- Besifloxacin
Topical ophthalmic demand is more resilient than oral demand because the products are used locally and remain relevant in bacterial conjunctivitis and other ophthalmic infections.
Otic competitors
Ofloxacin otic competes with:
- Ciprofloxacin otic
- Ciprofloxacin/dexamethasone
- Neomycin/polymyxin B/hydrocortisone
- Other topical otic anti-infective and anti-inflammatory products
Ofloxacin remains commercially useful in patients with tympanostomy tubes or a perforated tympanic membrane because of its topical profile and established labeling.
What generic entry risks affect FLOXIN?
Generic entry risk is no longer a future event. It is the central commercial condition for ofloxacin.
There is no meaningful Paragraph IV threat to a protected FLOXIN brand because the core patents have expired and generic products are already established. Any later Paragraph IV filing would ordinarily concern a new formulation, combination product, manufacturing process, or newly listed patent rather than the original ofloxacin molecule.
Generic manufacturers face several operational risks:
- FDA inspection and manufacturing compliance.
- Active pharmaceutical ingredient sourcing.
- Supply-chain concentration.
- Low margins caused by reimbursement pressure.
- Product discontinuation if volumes become uneconomic.
- Competition from other fluoroquinolones and non-fluoroquinolone antibiotics.
For purchasers, the more relevant risk is intermittent generic supply rather than patent-based launch delay.
What is the financial trajectory of FLOXIN?
FLOXIN’s financial trajectory has four phases: branded growth, generic erosion, systemic demand contraction, and residual topical demand.
Branded growth phase
During the original launch period, Daiichi benefited from branded pricing, physician familiarity, and broad antibacterial use. Systemic fluoroquinolones were prescribed across respiratory, urinary, skin, gastrointestinal, and sexually transmitted infections.
Generic erosion phase
Once generic ofloxacin entered the U.S. market, reimbursement systems and pharmacy substitution sharply reduced branded volume. Brand retention became difficult because ofloxacin is a small molecule with multiple generic alternatives and no delivery technology that creates a durable pricing premium.
Safety-driven contraction
FDA safety actions and antimicrobial stewardship reduced the use of oral fluoroquinolones in uncomplicated infections. The impact was structural rather than cyclical. Restrictions reduced the addressable market for systemic ofloxacin and constrained opportunities for brand revival.[1,2]
Residual topical phase
Ophthalmic and otic ofloxacin retain recurring demand. The revenue pool is fragmented among generic suppliers and is generally characterized by low unit prices, tender-driven purchasing, and limited brand loyalty.
No public financial reporting isolates FLOXIN revenue as a current standalone line item. Daiichi Sankyo’s modern financial disclosures focus on its current strategic portfolio, including oncology, cardiovascular, and immunology assets, rather than legacy ofloxacin sales.[4] Any current FLOXIN-branded revenue is therefore immaterial relative to the company’s consolidated business.
How strong is the FLOXIN patent estate?
The current patent estate is weak for commercial protection.
| Strength factor |
Assessment |
| Composition-of-matter protection |
Expired |
| Regulatory exclusivity |
Expired |
| Brand recognition |
Historical but commercially limited |
| Generic substitution resistance |
Low |
| Formulation differentiation |
Limited |
| Manufacturing barriers |
Moderate only for individual suppliers |
| Clinical differentiation |
Limited for oral use; more durable in selected topical uses |
| Litigation leverage |
Low |
| Pricing power |
Very low |
The residual value lies in manufacturing efficiency, regulatory compliance, distribution reliability, and procurement contracts. It does not lie in patent exclusivity.
What patent litigation and settlement agreements affect FLOXIN?
There is no current, material U.S. patent litigation preventing generic ofloxacin entry. Historical litigation may have accompanied generic approvals or patent challenges, but those disputes no longer define the market.
No active settlement agreement is known to create a delayed generic-entry date for the original FLOXIN molecule. Any assessment of a specific historical Paragraph IV case must be tied to the relevant dosage form and patent listing because oral, ophthalmic, and otic products were regulated through separate applications.
What biosimilar risk exists for FLOXIN?
FLOXIN has no biosimilar risk because ofloxacin is a chemically synthesized small molecule, not a biologic. The relevant competitive category is generic substitution under the abbreviated new drug application pathway.
This distinction matters commercially:
- Biosimilar litigation is not relevant.
- Patent-linkage litigation is largely historical.
- Therapeutic-equivalence ratings and pharmacy substitution are the key U.S. market mechanisms.
- Manufacturing cost and supply reliability matter more than clinical differentiation.
How does FLOXIN compare with ciprofloxacin and levofloxacin?
| Factor |
Ofloxacin/FLOXIN |
Ciprofloxacin |
Levofloxacin |
| U.S. brand status |
Legacy/discontinued commercial brand |
Legacy branded and generic products |
Legacy branded and generic products |
| Patent position |
Expired |
Expired |
Expired |
| Oral demand |
Reduced |
Larger historical generic base |
Larger historical generic base |
| Topical demand |
Ophthalmic and otic relevance |
Strong ophthalmic and otic competition |
Primarily systemic use |
| Safety pressure |
Class-wide fluoroquinolone restrictions |
Class-wide restrictions |
Class-wide restrictions |
| Current pricing power |
Minimal |
Minimal |
Minimal |
| Growth outlook |
Flat to declining |
Mature generic |
Mature generic |
Ofloxacin’s strongest remaining position is in topical ophthalmic and otic products. Its weakest position is oral systemic therapy, where competing fluoroquinolones and non-fluoroquinolone antibiotics limit volume.
What generic launch scenarios exist for FLOXIN?
Because generic entry has already occurred, future scenarios concern supply and portfolio rationalization:
- Continued multi-source generic supply with low prices.
- Manufacturer exits caused by thin margins.
- Temporary shortages caused by API or manufacturing disruptions.
- Stable ophthalmic and otic demand from institutional and retail channels.
- Continued oral volume decline from safety restrictions and stewardship.
- Limited relaunch potential unless a manufacturer introduces a differentiated delivery system or combination product.
A new branded strategy based solely on oral ofloxacin is commercially weak. A topical product could have more value if it combines formulation differentiation, convenient dosing, preservative-free delivery, or a clinically supported combination. Such a product would require new regulatory and patent analysis separate from legacy FLOXIN.
What is the geographic coverage of FLOXIN?
Ofloxacin has had broad international use under different brand names and generic labels. The strength of the original FLOXIN brand varies by country because patent terms, regulatory approvals, reimbursement systems, and local manufacturers differ.
The U.S. market is the most relevant for Orange Book and Paragraph IV analysis. In Europe and Asia, generic penetration and local-brand competition are also substantial. Daiichi Sankyo’s current commercial strategy is not centered on ofloxacin, and global revenue from legacy ofloxacin products is not separately reported in current corporate disclosures.
Key Takeaways
- FLOXIN is the legacy brand for ofloxacin, a fluoroquinolone antibiotic.
- U.S. composition-of-matter and regulatory exclusivity have expired.
- Generic ofloxacin is established across oral, ophthalmic, and otic dosage forms.
- Oral demand has declined because of FDA safety warnings, antimicrobial stewardship, and competing antibiotics.
- Ophthalmic and otic products retain residual demand but have limited pricing power.
- No current Paragraph IV event, biosimilar threat, or major patent litigation controls market access.
- FLOXIN has no meaningful separately reported current revenue stream.
- The commercial opportunity is concentrated in manufacturing efficiency, supply reliability, and selected topical formulations.
FAQs
Is FLOXIN still sold in the United States?
The original FLOXIN brand is not a meaningful current U.S. commercial product. Generic ofloxacin products remain available, subject to dosage form and manufacturer.
Is ofloxacin still protected by patents?
The original ofloxacin compound and core product protections have expired. Specific later patents could cover a particular formulation or manufacturing process, but they do not protect the legacy FLOXIN franchise broadly.
Can a generic manufacturer launch ofloxacin without a Paragraph IV challenge?
Yes. Because the core patents have expired, a generic manufacturer can rely on an abbreviated new drug application pathway without waiting for a current brand patent dispute involving the original FLOXIN product.
Is FLOXIN safer than ciprofloxacin?
Both are fluoroquinolones and carry class-related systemic safety warnings. Safety selection depends on the infection, dosage form, patient factors, resistance patterns, and available alternatives.
Does Daiichi Sankyo still generate material revenue from FLOXIN?
Current public financial reporting does not identify FLOXIN as a material revenue contributor. Daiichi Sankyo’s reported business is concentrated in newer strategic products rather than legacy ofloxacin sales.
References
-
U.S. Food and Drug Administration. (2016). FDA updates warnings for oral and injectable fluoroquinolone antibiotics due to disabling side effects. https://www.fda.gov
-
U.S. Food and Drug Administration. (2021). Fluoroquinolone antibacterial drugs: Drug safety communication regarding aortic aneurysm and dissection risk. https://www.fda.gov
-
U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations, 44th ed. [Orange Book]. https://www.fda.gov
-
Daiichi Sankyo Co., Ltd. (2024). Annual report and corporate financial information. https://www.daiichisankyo.com
-
National Library of Medicine. (2024). DailyMed: Ofloxacin drug labels. https://dailymed.nlm.nih.gov
